Integrated genomic characterization of papillary thyroid carcinoma.

Integrated genomic characterization of papillary thyroid carcinoma.
复制标题

DOI:
10.1016/j.cell.2014.09.050
复制
发表时间:
2014-10-23
期刊:
影响因子:
64.5
通讯作者:
Cancer Genome Atlas Research Network
Cancer Genome Atlas Research Network
中科院分区:
生物学1区
文献类型:
--
作者:
Cancer Genome Atlas Research Network

文献摘要

参考文献

被引文献

相似文献

甲状腺乳头状癌(PTC)是最常见的甲状腺癌类型。在这里,我们描述了496个PTC的基因组景观。我们观察到较低频率的体细胞改变(相对于其他癌症),并将已知的PTC驱动改变的集合扩展到包括EIF1AX,PPM1D和CHEK 2以及不同的基因融合。这些发现将具有未知致癌驱动因素的PTC病例的比例从25%降低到3.5%。基因组变异、基因表达和甲基化的组合分析表明,不同的驱动基团导致具有不同信号传导和分化特征的不同病理。同样,我们确定了BRAF突变肿瘤的不同分子亚组,多维分析强调了低分化亚组中oncomiR的潜在参与。我们的研究结果提出了将甲状腺癌重新分类为分子亚型,以更好地反映其潜在的信号传导和分化特性,这有可能改善其病理分类并更好地为疾病的管理提供信息。
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we describe the genomic landscape of 496 PTCs. We observed a low frequency of somatic alterations (relative to other carcinomas) and extended the set of known PTC driver alterations to include EIF1AX, PPM1D and CHEK2 and diverse gene fusions. These discoveries reduced the fraction of PTC cases with unknown oncogenic driver from 25% to 3.5%. Combined analyses of genomic variants, gene expression, and methylation demonstrated that different driver groups lead to different pathologies with distinct signaling and differentiation characteristics. Similarly, we identified distinct molecular subgroups of BRAF-mutant tumors and multidimensional analyses highlighted a potential involvement of oncomiRs in less-differentiated subgroups. Our results propose a reclassification of thyroid cancers into molecular subtypes that better reflect their underlying signaling and differentiation properties, which has the potential to improve their pathological classification and better inform the management of the disease.
DOI: 10.1056/nejmoa1209288
发表时间: 2013-02-14
期刊: The New England journal of medicine
影响因子: --
作者:
Ho AL;Grewal RK;Leboeuf R;Sherman EJ;Pfister DG;Deandreis D;Pentlow KS;Zanzonico PB;Haque S;Gavane S;Ghossein RA;Ricarte-Filho JC;Domínguez JM;Shen R;Tuttle RM;Larson SM;Fagin JA
通讯作者: Fagin JA
DOI: 10.1038/sj.onc.1208822
发表时间: 2005-10-06
期刊: ONCOGENE
影响因子: 8
作者:
Giordano, TJ;Kuick, R;Nikiforov, YE
通讯作者: Nikiforov, YE
DOI: 10.1093/jnci/95.8.625
发表时间: 2003-04-16
期刊: JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子: --
作者:
Cohen, J;Xing, MZ;Sidransky, D
通讯作者: Sidransky, D
DOI: 10.1097/01.pas.0000176432.73455.1b
发表时间: 2006-02-01
影响因子: 5.6
作者:
Adeniran, AJ;Zhu, ZW;Nikiforov, YE
通讯作者: Nikiforov, YE
DOI: 10.1073/pnas.1321937111
发表时间: 2014-03-18
影响因子: 11.1
作者:
Kelly, Lindsey M.;Barila, Guillermo;Nikiforov, Yuri E.
通讯作者: Nikiforov, Yuri E.